First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis.
Background: Hepatocellular carcinoma poses a significant public health burden in China, necessitating the economic evaluation of new therapeutic strategies for policy-makers and clinicians. The international, randomized phase 3 trial CARES-310 revealed that camrelizumab plus rivoceranib provided a s...
| Published in: | Clinical Medicine Insights: Oncology pp. 1 - 12 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Sage Publications Inc.
11/23/2024
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=181053470&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 181053470 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11795549 B3KT jtl: Clinical Medicine Insights: Oncology issn: 11795549 maglogo: Y pubinfo: dt: 11/23/2024 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 181053470 181053470 181053470 10.1177/11795549241299393 181053470 ppf: 1 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis. aug: au: Xiang, Guiyuan Huang, Yueyue Zhang, Ni Du, Xinyu Wu, Yuanlin Gan, Lanlan Li, Yanping Jiang, Tingting Liu, Yao affil: Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China sug: subj: Carcinoma, Hepatocellular Drug Therapy Cost Effectiveness Analysis Antibodies, Monoclonal Economics Tyrosine Kinase Inhibitors Economics Antineoplastic Agents, Combined Economics Sorafenib Economics Antibodies, Monoclonal Therapeutic Use Tyrosine Kinase Inhibitors Therapeutic Use Antineoplastic Agents, Combined Therapeutic Use Sorafenib Therapeutic Use Human China Funding Source Treatment Outcomes Disease Progression Quality-Adjusted Life Years Univariate Statistics Multivariate Statistics Descriptive Statistics ab: Background: Hepatocellular carcinoma poses a significant public health burden in China, necessitating the economic evaluation of new therapeutic strategies for policy-makers and clinicians. The international, randomized phase 3 trial CARES-310 revealed that camrelizumab plus rivoceranib provided a substantial clinical benefit in patients with advanced hepatocellular carcinoma, but the economic outcome remains unclear. This study aimed to evaluate the cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CARES-310) from the perspective of the Chinese health care system. Methods: A partitioned survival model was developed to estimate the lifetime cost and clinical outcomes of camrelizumab plus rivoceranib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma. Survival data from the CARES-310 trial were used to create a hypothetical cohort of 543 patients with advanced hepatocellular carcinoma for modeling disease progression. The life-year, quality-adjusted life-year (QALY), incremental cost-effectiveness ratio (ICER) was used to measure the model's outcome, with the willingness-to-pay threshold set at 3 times China's gross domestic product (GDP) per capita (US$36 780). Univariate, multivariable probabilistic sensitivity analyses, and subgroup analysis were performed to assess parameter uncertainty, complemented by a scenario analysis using health utilities reported in literature. Results: The camrelizumab group yielded an additional 0.239 QALYs at an added cost of US$8340 compared with sorafenib, resulting in an ICER of US$34 897/QALY. Univariate sensitivity analysis indicated that the model results were most sensitive to the utility of progression-free survival in the camrelizumab group, sorafenib cost, and camrelizumab cost. Probabilistic sensitivity analysis revealed a 56% probability of cost-effectiveness of camrelizumab plus rivoceranib among all patients. The results of the subgroup analysis demonstrated camrelizumab plus rivoceranib was the most cost-effective in the subgroup with albumin-bilirubin grade 2. Conclusions: At a willingness-to-pay threshold of US$36 780/QALY, camrelizumab plus rivoceranib is likely to be a cost-effective option compared with sorafenib as first-line treatment for advanced hepatocellular carcinoma in China. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|